Health Canada

What Health Canada does

Health Canada is the federal department of the Government of Canada responsible for helping Canadians maintain and improve their health, headquartered in Ottawa with 10,000+ employees. It serves as Canada's national regulatory authority for therapeutic products, operating under the Food and Drugs Act, Cannabis Act, Biocides Regulations, and Pest Control Products Act. Its core operational assets include the Drug and Health Product Portal (DHPP) — a public-facing platform integrating the Drug Product Database, Medical Device Active License Listing (MDALL), Market Authorized Biocides Database, National Wastewater Drug Surveillance dashboard, adverse event reporting systems, and over 2,660 published review decisions. The department processes market authorization submissions for drugs, generics, biosimilars, biologics, medical devices, natural health products, and clinical trials, and operates complementary public health programs including the Canadian Dental Care Plan (covering 6+ million Canadians) and the Climate Change and Health Capacity Building programme.

The department does not generate commercial revenue; it is funded through annual parliamentary appropriations. Its "go-to-market" consists of regulatory pathways (Priority Review, Notice of Compliance with Conditions, standard review) through which pharmaceutical, biotech, and medical device companies seek market authorization. Customer segments span Canadian residents (universal public health protection), healthcare professionals (adverse event reporting, safety information access), and industry stakeholders (manufacturers seeking Drug Establishment Licenses and Medical Device Licenses). Communication occurs through the Canada.ca portal, public advisories, recalls, public consultations, and the NWDS dashboard.

Recent strategic activity reflects a dual mandate of expansion and contraction: regulatory scope is broadening through new frameworks (Biocides Regulations effective 2025-05-31, draft Clinical Trial Regulations 2025-12-20, Bill S-5 Connected Care Act 2026-02-04, Pharmaceutical and Life Sciences Sector Task Force 2026-03-18), while headcount is contracting by 942 FTEs over three years under the Carney government spending review. Notable approvals in 2025-2026 include the first generic semaglutide in the G7, Zepbound for sleep apnea, Kisunla for Alzheimer's, VIMKUNYA chikungunya vaccine, neffy epinephrine nasal spray, and multiple biosimilars.

Name

Health Canada

Legal name

Health Canada

Website

https://dhpp.hpfb-dgpsa.ca

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Health Canada is Canada's federal health regulatory department, headquartered in Ottawa, responsible for approving and monitoring drugs, medical devices, biologics, natural health products, and biocides, and for delivering public health programs serving all Canadian residents.

Ownership category

akta.pro rank

Product category

Health Product Regulatory Authority

NAICS

Administration of Public Health Programs (92312), Administration of Public Health Programs (923120)

SIC

Services-Health Services (8000), Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Healthcare Quality & Patient Safety Regulators (HLAJACAD)

akta.pro secondary industries

Drug Regulators (Human Pharmaceuticals) (HLAJADAA), Medical Device Regulators (HLAJADAC), Regulatory Compliance, Licensing & Enforcement (Public Health) (HLAJAMAE), Health Data Privacy, Security & Interoperability Regulators (HLAJACAE)

Keywords

• Health product regulation
• Drug safety oversight
• Medical device licensing
• Pharmaceutical regulatory approval
• Public health protection

Headquarters

HQ city

Ottawa

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. Government Funding: Health Canada operates as a federal government department funded through annual parliamentary appropriations. The department receives budget allocations for regulatory functions, public health initiatives, and program delivery.
2. Regulatory Fees: Health Canada collects fees for drug submissions, medical device licenses, establishment licenses, and other regulatory services. Revenue supports regulatory review and compliance activities.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Health Canada is the federal regulatory authority that evaluates and authorizes drugs, medical devices, biologics, natural health products, and biocides for the Canadian market through licensing, market authorization, and post-market surveillance. It issues Drug Establishment Licenses, Medical Device Licenses, and Notices of Compliance, and operates public regulatory databases (Drug Product Database, MDALL, MABD) along with the Drug and Health Product Portal for transparency and adverse event reporting.

Product overview

Health Canada's Drug and Health Products Portal (DHPP) is a regulatory information platform that provides public access to information about health products authorized in Canada. The portfolio consists primarily of searchable databases and regulatory decision repositories, including the Drug Product Database for human drugs, Medical Device Active License Listing (MDALL) for medical devices, and the Market Authorized Biocides Database (MABD) for biocides. The portal also provides access to Regulatory Decision Summaries, Summary Basis of Decisions, and Summary Safety Reviews documenting the rationale for Health Canada's regulatory decisions. The system serves consumers, healthcare professionals, and researchers seeking information about drug safety, effectiveness, ingredients, side effects, and regulatory status.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug and Health Products Portal (DHPP) Government portal providing public access to regulatory information about drugs, natural health products, medical devices, and biocides authorized for sale in Canada, with improved search, accessibility, daily updates, and links to regulatory decisions.
• Drug Product Database

Quantifiable outcome

• Canadian Dental Care Plan coverage expanded to over 6 million Canadians with average savings of $900 per year
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• University of British Columbia and BC Provincial Health Services AuthoritycoreStrategic or Co-development Partner · 28 June 2026Health Canada allocated over $13 million through HeatADAPT to UBC and BC's Provincial Health Services Authority to study extreme heat health risks as part of the Climate Change and Health Capacity Building programme.
• DiaMedica TherapeuticsminorStrategic or Co-development Partner · 30 March 2026Health Canada granted regulatory approval for a Phase 2 DM199 study in early-onset preeclampsia, supporting clinical research development in Canada.
• Synklino A/SminorStrategic or Co-development Partner · 25 February 2026Health Canada granted regulatory clearance for Phase 1 clinical trials of SYN002 in kidney transplantation, with Canadian study led by Dr. Atul Humar at UHN Toronto expected to enroll first patient in April 2026.
• Movember CanadacoreStrategic or Co-development Partner · 23 February 2026The Government of Canada, through Health Canada, partnered with Movember Canada as an independent convening stakeholder for the national conversation on men and boys' health to inform Canada's first Men and Boys' Health Strategy expected in 2026.
• ALK-AbellócoreOEM/ Whitelabel/ Licensing Partner · 1 November 2024ALK-Abelló holds exclusive licensing rights to commercialize neffy (epinephrine nasal spray) in Canada following Health Canada approval. The company expects to launch the product in summer 2026, potentially benefiting over 2.5 million Canadians with severe allergies.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• U.S. Food and Drug Administration: The federal regulatory authority in the United States responsible for protecting public health by ensuring the safety, efficacy, and security of drugs, biologics, medical devices, and food — the most direct international counterpart to Health Canada in scope, mandate, and product categories regulated.
• European Medicines Agency: The EU agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use. Closely comparable to Health Canada's Health Products and Food Branch in regulatory remit across drugs and biologics.
• UK Medicines and Healthcare products Regulatory Agency: The UK's regulator for medicines, medical devices, and blood components for transfusion. Operates with a near-identical product-safety regulatory scope to Health Canada and serves as a Commonwealth peer with shared legal traditions.
• Therapeutic Goods Administration (Australia): Australia's regulatory authority for therapeutic goods including prescription medicines, vaccines, medical devices, and biologics. Comparable in mandate and operates under similar Commonwealth government funding models with analogous cost-recovery fee structures.
• Health Products Regulatory Authority (Ireland): Ireland's regulator for medicines, medical devices, and cosmetics. Comparable in product scope and operates as a national competent authority within the EU system, with similar fee-for-service revenue model and adverse-event reporting mandate.

Regional players

• Pharmaceuticals and Medical Devices Agency (Japan): Japan's regulatory agency for pharmaceuticals and medical devices. Operates a comparable review-and-approval mandate with distinct regional procedural standards; Health Canada increasingly benchmarks PMDA review timelines in Pacific Rim filings.
• Swissmedic: Switzerland's therapeutic products regulator with authority over medicinal products and medical devices. Operates a smaller-scale but functionally analogous regulatory regime and is frequently cited as a peer in Mutual Recognition Agreement (MRA) discussions.
• Central Drugs Standard Control Organisation (India): India's national regulatory authority for pharmaceuticals and medical devices. Functions as a high-volume, emerging-market analogue with a comparably broad product-safety mandate to Health Canada.

Broad incumbents

• Public Health Agency of Canada: The Canadian federal agency responsible for public health promotion, disease prevention, and emergency preparedness. An adjacent Canadian public health peer with overlapping scope in population health, immunization, and crisis response that intersects with Health Canada's regulatory mandate.

Others

• Canadian Institute for Health Information: An independent, not-for-profit organization that provides comparable health system data and analytics in Canada. Functions as an enabling data-infrastructure peer to Health Canada's database portfolio (DPD, MDALL, NWDS) and supports interoperability initiatives such as those contemplated under Bill S-5.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/healthcanada
• Facebookfacebook.com/HealthyCdns
• LinkedInlinkedin.com/company/health-canada

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments42 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Health Canada